SCHEMBL5510101

SCHEMBL5510101

COc1cccc(-c2ccc3c(c2)c(-c2nc4c(O)cccc4[nH]2)nn3COCC[Si](C)(C)C)c1C

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MGAM O43451 4/20 0.39
▸ GAA P10253 4/20 0.39
▸ SI P14410 4/20 0.39
▸ MGAM2 Q2M2H8 4/20 0.39
▸ CDK2 P24941 12/20 0.37
▸ CDK4 P11802 8/20 0.37
▸ CCNA2 P20248 8/20 0.37
▸ CCND1 P24385 8/20 0.37
▸ CCND3 P30281 8/20 0.37
▸ PRKCZ Q05513 5/20 0.37
▸ CHEK1 O14757 2/20 0.36
▸ KDR P35968 2/20 0.36
▸ PARP1 P09874 3/20 0.35
▸ FGFR1 P11362 1/20 0.34
▸ JAK2 O60674 1/20 0.34
▸ JAK1 P23458 1/20 0.34
▸ TYK2 P29597 1/20 0.34
▸ JAK3 P52333 1/20 0.34
▸ HPSE Q9Y251 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14493382 0.89 CDK2 (0.41) CDK2CDK4CCNA2CCND1CCND3
SCHEMBL5514214 0.87 CDK1 (0.38) MGAMGAASIMGAM2CDK2
SCHEMBL5510595 0.83 ATR (0.33) MGAMGAASIMGAM2CDK2
SCHEMBL14493562 0.78 CDK4 (0.44) CDK2CDK4CCNA2CCND1CCND3
SCHEMBL5518527 0.76 CDK4 (0.43) CDK2CDK4CCNA2CCND1CCND3
SCHEMBL5523694 0.76 CDK2 (0.52) MGAMGAASIMGAM2CDK2
SCHEMBL5513196 0.75 CDK1 (0.54) KDR
SCHEMBL14493472 0.74 CDK1 (0.36) CDK2CDK4CCNA2CCND1CCND3
SCHEMBL5516217 0.74 CDK4 (0.40) CDK2CDK4CCNA2CCND1CCND3
SCHEMBL14493377 0.74 SMN1; SMN2 (0.49) GAACHEK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7232912-B2 Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation AGOURON PHARMACEUTICALS, INC. (US) 2007-06-19 — — US disclosed
US-7232912-B2 Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation AGOURON PHARMACEUTICALS, INC. (US) 2007-06-19 — — US disclosed
US-7232912-B2 Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation AGOURON PHARMACEUTICALS, INC. (US) 2007-06-19 — — US disclosed
US-20060111322-A1 Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation AGOURON PHARMACEUTICALS, INC. 2006-05-25 — — US disclosed
US-20050239855-A1 Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation AGOURON PHARMACEUTICALS, INC. 2005-10-27 — — US disclosed
US-6919461-B2 Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation AGOURON PHARMACEUTICALS, INC. (US) 2005-07-19 — — US disclosed
US-20030139463-A1 Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation REICH SIEGFRIED HEINZ (US) 2003-07-24 — — US disclosed
US-6555539-B2 For treating cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, psoriasis AGOURON PHARMACEUTICALS 2003-04-29 — — US disclosed
US-20020161022-A1 Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation AGOURON PHARMACEUTICALS 2002-10-31 — — US disclosed
EP-1250326-A2 INDAZOLE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND THEIR USE FOR MEDIATING OR INHIBITING CELL PROLIFERATION AGOURON PHARMACEUTICALS, INC. (US) 2002-10-23 — — EP disclosed
WO-2001053268-A2 INDAZOLE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND THEIR USE FOR MEDIATING OR INHIBITING CELL PROLIFERATION AGOURON PHARMACEUTICALS, INC. (US) 2001-07-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050239855-A1 Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation CDK3, MKI67, ROCK1 MGAM 2936/4885GAA 2014/4885SI 1223/4885
US-20020161022-A1 Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation CDK3, MKI67, ROCK1 MGAM 2936/4885GAA 2014/4885SI 1223/4885
US-20030139463-A1 Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation CDK3, MKI67, ROCK1 MGAM 2936/4885GAA 2014/4885SI 1223/4885
US-20060111322-A1 Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation MKI67, CCNI, CDK3 MGAM 3569/4885GAA 2126/4885SI 578/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback